<DOC>
	<DOCNO>NCT00428415</DOCNO>
	<brief_summary>Purpose : To evaluate effect tesofensine energy balance</brief_summary>
	<brief_title>Effect Tesofensine Energy Balance Humans .</brief_title>
	<detailed_description />
	<criteria>Overweight obese subject BMI 28 35 kg/m² otherwise healthy Males 18 50 year age , extremes included Subjects able comply study procedure Subjects give write informed consent Use concomitant medication include high dose vitamin regular OTC preparation Subjects smoker within last year Subjects specific disease interfere metabolism e.g . myxoedema , Cushing 's syndrome , Type 1 diabetes mellitus , significant neurological psychiatric illness epilepsy , schizophrenia , depression , eat disorder bulimia . Subjects Type 2 diabetes mellitus ineligible unless antidiabetic medication deem necessary investigator fasting ( venous arterialize capillary full blood finger ear ) blood glucose &gt; 6.1 mmol/l screening . Retest allow first measure inclusion value . The corresponding exclusion criterion plasma glucose 7.0 mmol/l Known hypercholesterolaemia ( &gt; 7 mmol/l ) . Known hypertriglyceridaemia ( &gt; 3 mmol/l ) . Malabsorptive intestinal disorder assume affect absorption tesofensine Mental psychiatric disorder base medical history Subjects systemic infection inflammatory disease Subjects currently ( within past 2 month ) know abuse dependent drug , include alcohol ( weekly consumption &gt; 21 unit alcohol ) Hepatic renal dysfunction ( ASAT and/or ALAT &gt; 2 x ULN creatinine clearance &lt; 30 mL/min estimate central laboratory use Cockcroft Gault formula , respectively ) Special diet ( e.g. , vegetarian , Atkins ) Subject athletics plan major change physical activity study extent may interfere study outcome , judge investigator Weight change &gt; 3 kg within 2 month prior screen Surgically treat obesity History presence significant cardiovascular disease heart failure , ischemic heart disease , stroke , transient ischemic attack Significant abnormality ECG accord investigator opinion . Additional exclusionary ECG value : QTcB &gt; 450 millisecond ( m ) , PR interval &gt; 240 m , QRS interval &gt; 120 m Hypotension ( i.e . supine systolic BP &lt; 90 mm Hg ) and/or symptomatic orthostatic hypotension ( clinical symptom orthostatic hypotension associate decline ≥ 20 mm Hg systolic BP one minute standing compare previous supine systolic BP obtain 5 minute quiet rest ) screen visit Hypertension ( i.e . sit diastolic BP ≥ 95 mm Hg sit systolic BP ≥ 155 mm Hg ) well HR &gt; 90 bpm Known HIV infection ( test require ) Clinically significant potentially disable eye disorder , include uncontrolled glaucoma Serologic evidence active hepatitis B and/or C History cancer within past 5 year , exclude treat basal cell carcinoma Subjects previously treat tesofensine Subjects treat investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>